To understand and ultimately improve therapeutic efficacy, we quantified therapy-induced gene program changes in non-dysfunctional tumor-reactive CD8+ T cells, a subset of T cells that recognize tumor-associated antigens16 and are also cytotoxic17,18. Here, CD8A is linked to neoplasm.